Chemokine receptor 2–targeted molecular imaging in pulmonary fibrosis. A clinical trial
SL Brody, SP Gunsten, HP Luehmann… - American journal of …, 2021 - atsjournals.org
Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive inflammatory lung disease
without effective molecular markers of disease activity or treatment responses. Monocyte …
without effective molecular markers of disease activity or treatment responses. Monocyte …
Chemokine Receptor 2-targeted Molecular Imaging in Pulmonary Fibrosis. A Clinical Trial
SL Brody, SP Gunsten… - … of respiratory and …, 2021 - pubmed.ncbi.nlm.nih.gov
Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive inflammatory lung disease
without effective molecular markers of disease activity or treatment responses. Monocyte …
without effective molecular markers of disease activity or treatment responses. Monocyte …
[PDF][PDF] Chemokine receptor 2-targeted molecular imaging in pulmonary fibrosis
scholar.archive.org
Idiopathic pulmonary fibrosis (IPF) is a progressive, inflammatory lung disease that is
monitored clinically by measures of lung function, without effective molecular markers of …
monitored clinically by measures of lung function, without effective molecular markers of …
Chemokine Receptor 2–targeted Molecular Imaging in Pulmonary Fibrosis
SL Brody, SP Gunsten, HP Luehmann… - American journal of …, 2021 - profiles.wustl.edu
Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive inflammatory lung disease
without effective molecular markers of disease activity or treatment responses. Monocyte …
without effective molecular markers of disease activity or treatment responses. Monocyte …
Chemokine Receptor 2–targeted Molecular Imaging in Pulmonary Fibrosis
SL Brody, SP Gunsten… - … and critical care …, 2021 - utsouthwestern.elsevierpure.com
Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive inflammatory lung disease
without effective molecular markers of disease activity or treatment responses. Monocyte …
without effective molecular markers of disease activity or treatment responses. Monocyte …
[HTML][HTML] Chemokine Receptor 2–targeted Molecular Imaging in Pulmonary Fibrosis. A Clinical Trial
SL Brody, SP Gunsten, HP Luehmann… - American Journal of …, 2021 - ncbi.nlm.nih.gov
Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive inflammatory lung disease
without effective molecular markers of disease activity or treatment responses. Monocyte …
without effective molecular markers of disease activity or treatment responses. Monocyte …
Chemokine receptor 2-targeted molecular imaging in pulmonary fibrosis
SL Brody, SP Gunsten, HP Luehmann, DH Sultan… - bioRxiv, 2020 - biorxiv.org
Idiopathic pulmonary fibrosis (IPF) is a progressive, inflammatory lung disease that is
monitored clinically by measures of lung function, without effective molecular markers of …
monitored clinically by measures of lung function, without effective molecular markers of …
Chemokine Receptor 2-targeted Molecular Imaging in Pulmonary Fibrosis. A Clinical Trial.
SL Brody, SP Gunsten, HP Luehmann… - American Journal of …, 2021 - europepmc.org
Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive inflammatory lung disease
without effective molecular markers of disease activity or treatment responses. Monocyte …
without effective molecular markers of disease activity or treatment responses. Monocyte …
[引用][C] Chemokine Receptor 2–targeted Molecular Imaging in Pulmonary Fibrosis. A Clinical Trial
S Brody, S Gunsten, H Luehmann, D Sultan… - American Journal of …, 2021 - hal.science
Chemokine Receptor 2–targeted Molecular Imaging in Pulmonary Fibrosis. A Clinical Trial -
Archive ouverte HAL Accéder directement au contenu Documentation FR Français (FR) …
Archive ouverte HAL Accéder directement au contenu Documentation FR Français (FR) …
Chemokine receptor 2-targeted molecular imaging in pulmonary fibrosis
SL Brody, SP Gunsten, HP Luehmann, DH Sultan… - 2020 - europepmc.org
Idiopathic pulmonary fibrosis (IPF) is a progressive, inflammatory lung disease that is
monitored clinically by measures of lung function, without effective molecular markers of …
monitored clinically by measures of lung function, without effective molecular markers of …